NVS - Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study | Benzinga
Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patients with IgA nephropathy (IgAN).
IgAN is a major cause of chronic kidney disease and kidney failure and mostly affects young adults.
Atrasentan, an investigational oral endothelin A receptor antagonist in development for IgAN and other rare kidney diseases, was added to the Novartis portfolio through the recent